Addex Therapeutics Ltd. (ADXN)
2.90
-0.07
(-2.36%)
USD |
NASDAQ |
Oct 26, 16:00
3.07
+0.17
(+5.86%)
After-Hours: 20:00
Addex Therapeutics Enterprise Value : 2.224M for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 2.224M |
| October 23, 2026 | 2.298M |
| October 22, 2026 | 2.216M |
| October 21, 2026 | 2.320M |
| October 20, 2026 | 2.383M |
| October 19, 2026 | 2.213M |
| October 16, 2026 | 2.075M |
| October 15, 2026 | 2.351M |
| October 14, 2026 | 1.959M |
| October 13, 2026 | 2.341M |
| October 12, 2026 | 2.373M |
| October 09, 2026 | 2.562M |
| October 08, 2026 | 2.521M |
| October 07, 2026 | 2.468M |
| October 06, 2026 | 2.521M |
| October 05, 2026 | 2.436M |
| October 02, 2026 | 2.404M |
| October 01, 2026 | 2.309M |
| September 30, 2026 | 2.075M |
| September 29, 2026 | 2.277M |
| September 28, 2026 | 2.128M |
| September 25, 2026 | 3.020M |
| September 24, 2026 | 2.819M |
| September 23, 2026 | 2.808M |
| September 22, 2026 | 2.861M |
| Date | Value |
|---|---|
| September 21, 2026 | 2.893M |
| September 18, 2026 | 2.755M |
| September 17, 2026 | 2.712M |
| September 16, 2026 | 2.712M |
| September 15, 2026 | 2.606M |
| September 14, 2026 | 2.840M |
| September 11, 2026 | 2.850M |
| September 10, 2026 | 2.744M |
| September 09, 2026 | 2.978M |
| September 08, 2026 | 3.074M |
| September 04, 2026 | 3.020M |
| September 03, 2026 | 3.084M |
| September 02, 2026 | 2.882M |
| September 01, 2026 | 3.020M |
| August 31, 2026 | 3.307M |
| August 28, 2026 | 3.222M |
| August 27, 2026 | 3.233M |
| August 26, 2026 | 3.636M |
| August 25, 2026 | 3.286M |
| August 24, 2026 | 3.445M |
| August 21, 2026 | 4.390M |
| August 20, 2026 | 3.997M |
| August 19, 2026 | 5.197M |
| August 18, 2026 | 5.197M |
| August 17, 2026 | 5.197M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novartis AG | 323.28B |
| Roche Holding AG | -- |
| Oculis Holding AG | 211.49M |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.207M |
| Revenue (Quarterly) | 0.0126M |
| Total Expenses (Quarterly) | 2.22M |
| EPS Diluted (Quarterly) | -2.160 |
| Gross Profit Margin (Quarterly) | -153.2% |
| Profit Margin (Quarterly) | -17.52K% |
| Earnings Yield | -303.8% |
| Normalized Earnings Yield | -303.79 |